U.S. R&D headcount tumbles in key categories

Pharmalot has been crunching the numbers for R&D jobs and concludes that the U.S. is seeing a considerable amount of shrinkage in the field. Looking at new numbers from PhRMA for 2006, R&D employment among its members dropped 3.9 percent. And there were a number of sizable reductions last year, with the axe expected to drop again over the course of 2008.

RPM concludes that the biggest cutbacks in R&D are occurring in the approval and post-marketing phases. The money spent on R&D in the U.S. continues to rise, but after an 11.3 percent hike in 2006 budgets rose only 2.7 percent to a still considerable $35.4 billion.

- read the report from Pharmalot
- see the PhRMA report (.pdf)

Related Articles:
Top 8 layoffs of 2007
The Top 15 R&D Budgets
Big Pharma's biotech shift means layoffs for chemists
Ranks of sales reps thinning

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.